Inherited predispositions and hyperactive Ras in myeloid leukemogenesis

Pediatric Blood and Cancer

Volumn 46, Issue 5, 2006, Pages 579-585

  Lauchle, Jennifer O ^a   Braun, Benjamin S ^a   Loh, Mignon L ^a   Shannon, Kevin ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

JMML; Leukemia; Neurofibromatosis; Noonan syndrome; Ras

Indexed keywords

GUANOSINE TRIPHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER SUSCEPTIBILITY; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE MUTATION; GENETIC ENGINEERING; GENETIC PREDISPOSITION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; MYELOID LEUKEMIA; NEUROFIBROMATOSIS; NONHUMAN; NOONAN SYNDROME; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW;

ANIMALS; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MYELOPROLIFERATIVE DISORDERS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 33645280589     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20644     Document Type: Review

References (65)

1. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: Molecular understanding and prospects for therapy. Mol Med Today 1996;2:468-475.
2. Arico M, Biondi A, Pui C-H. Juvenile myelomonocytic leukemia. Blood 1997;90:479-488.
3. Emanuel PD, Bates LJ, Castleberry RP, et al. Seletive hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991;77:925-929.
4. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukemia/lymphoma: A population-based UKCCSG study. Br J Cancer 1994;70:969-972.
5. Bader-Meunier B, Tchernia G, et al. Occurrence of myeloproliferative disorder in patients with the Noonan syndrome. J Pediatr 1997;130:885-889.
6. Side LE, Shannon KM. Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled. J Pediatr 1997;130:857-859.
7. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
8. Bar-Sagi D. Ras proteins: Biological effects and biochemical targets. Anticancer Res 1989;9:1427-1437.
9. Satoh T. Nakafuku M, Miyajima A, et al. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci USA 1991;88:3314-3318.
10. Donovan S, Shannon KM, Bollag G. GTPase activating poteins: Critical regulators of intracellular signaling. BBA Rev Cancer 2002;1602:23-45.
11. ras. Blood 1994;84:3435-3439.
12. Miyauchi J, Asada M, Sasaki M, et al. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 1994;83:2248-2254.
13. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992;3:241-247.
14. Cichowski K, Jacks T. NF1 tumor suppressor gene function: Narrowing the GAP. Cell 2001;104:593-604.
15. Side L, Emanuel P, Taylor B, et al. Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1. Blood 1998;92:267-273.
16. Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr 1978;92:925-929.
17. Miles DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis, type 1, and malignant myeloid disorders. Blood 1996;88:4314-4320.
18. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
19. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997;336:1713-1720.
20. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nat Genet 1996;12:144-148.
21. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468.
22. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002;70:1555-1563.
23. Choong K, Freedman MH, Chitayat D, et al. Juvenile myelomonocytic leukemia and Noonan syndrome. J Pediatr Hematol Oncol 1999;21:523-527.
24. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004;103:2325-2331.
25. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia. Nat Genet 2003;34:148-150.
26. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003;28:284-293.
27. Van Vactor D, O'Reilly AM, Neel BG. Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev 1998;8:112-126.
28. Saxton TM, Henkemeyer M, Gasca S, et al. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 1997;16:2352-2364.
29. Saxton TM, Ciruna BG, Holmyard D, et al. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat Genet 2000;24:420-423.
30. Qu CK, Yu WM, Azzarelli B, et al. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol 1998;18:6075-6082.
31. Qu CK, Nguyen S, Chen J, et al. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 2001;97:911-914.
32. Qu CK. Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response. Biochim Biophys Acta 2002;1592:297-301.
33. Itoh T, Liu R, Yokota T, et al. Definition of the role of tyrosine residues of the common beta subunit regulating multiple signaling pathways of granulocyle-macrophage colony-stimulating factor receptor. Mol Cell Biol 1998;18:742-752.
34. Itoh T, Liu R, Arai K, et al. Differential influence of tyrosine residues of the common receptor beta subunit on multiple signals induced by human GM-CSF. J Allergy Clin Immunol 1999;103:S462-S470.
35. ras by myristoylation. Biochem Soc Trans 1989;17:867-869.
36. O'Reilly AM, Pluskey S, Shoelson SE, et al. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol Cell Biol 2000;20:299-311.
37. Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/ myeloproliferative disease. Blood 2005;106:2183-2185.
38. Mohi MG, Williams IR, Dearolf CR, et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005;7:179-191.
39. Schubbert S, Lieuw K, Rowe SL, et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005.
40. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type 1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-1029.
41. Jacks T, Shih S, Schmitt EM, et al. Tumorigenic and developmental consequences of a targeted Nf1 mutation in the mouse. Nat Genet 1994;7:353-361.
42. Largaespada DA, Brannan CI, Jenkins NA, et al. Nf1 deficiency causes Ras-mediated granulocyte-macrophage colony stimulating factor hypersensitivity and chronic myeloid leukemia. Nat Genet 1996;12:137-143.
43. Zhang Y, Vik TA, Ryder JW, et al. Nf1 regulates hematopoietic progenitor cell growth and Ras signaling in response to multiple cytokines. J Exp Med 1998;187:1893-1902.
44. Zhang Y, Taylor BR, Shannon K, et al. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. J Clin Invest 2001;108:709-715.
45. Birnbaum RA, O'Marcaigh A, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell 2000;5:189-195.
46. Mahgoub N, Taylor BR, Gratiot M, et al. In vitro and In vivo effects of a farnesyltransferase inhibitor on Nf1 - deficient hematopoietic cells. Blood 1999;94:2469-2476.
47. Zhu Y, Romero MI, Ghosh P, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001;15:859-876.
48. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-922.
49. Kuhn R, Schwenk F, Aguet M, et al. Inducible gene targeting in mice. Science 1995;269:1427-1429.
50. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004;103:4243-4250.
51. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-3248.
52. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:597-602.
53. Chan IT, Kutok JL, Williams IR, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113:528-538.
54. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004;10:849-857.
55. Chan RJ, Leedy MB, Munugalavadla V, et al. Human somatic PTPN11 mutations induce hematopoietic cell hypersensitivity to granulocyte-macrophage colony stimulating factor. Blood 2005.
56. Li S, Gillessen S, Tomasson MH, et al. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 2001;97:1442-1450.
57. Kelly L, Clark J, Gilliland DG. Comprehensive genotypic analysis of leukemia: Clinical and therapeutic implications. Curr Opin Oncol 2002;14:10-18.
58. Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996;85:853-861.
59. Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:2551-2556.
60. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002;1:63-74.
61. Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002;99:3801-3805.
62. Farr CJ, Saiki RK, Erlich HA, et al. Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc Natl Acad Sci USA 1988;85:1629-1633.
63. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 1988;2:503-510.
64. Bashey A, Gill R, Levi S, et al. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): Implications for the role of N-ras mutation in AML pathogenesis. Blood 1992;79:981-989.
65. Papayannopoulou T, Nakamoto B, Anagnou NP, et al. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood 1991;77:2569-2576.